Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 1209 results for criteria

  1. Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]

    Awaiting development Reference number: GID-TA11974 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Povorcitinib for treating non-segmental vitiligo [GID-TA12019]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Povorcitinib for treating prurigo nodularis [GID-TA12018]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lemborexan for treating insomnia [GID-TA12011]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [GID-TA12039]

    Awaiting development Reference number: GID-TA12039 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [GID-TA12040]

    Awaiting development Reference number: GID-TA12040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]

    Awaiting development Reference number: GID-TA12038 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]

    Awaiting development Reference number: GID-TA12033 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [GID-TA12031

    Awaiting development Reference number: GID-TA12031 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development